Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale-Reference-Cited by-同舟云学术

Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale

Published:2022-03 Issue: Volume:114 Page:106674
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Perez-Correa Andres,Abbas Bilal,Riback Lindsey,Ghiroli Megan,Norton Brianna,Murphy Sean,Jakubowski Andrea,Hayes Benjamin T.,Cunningham Chinazo O.,Fox Aaron D.

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference64 articles.

1. Treatment utilization among persons with opioid use disorder in the United States;Wu;Drug Alcohol Depend.,2016

2. NAM Perspectives. Discussion Paper, Washington, DC;Madras,2020

3. Increases in drug and opioid-involved overdose deaths - United States, 2010-2015;Rudd;MMWR Morb. Mortal. Wkly Rep.,2016

4. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013;Saloner;JAMA,2015

5. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial;Liebschutz;JAMA Intern. Med.,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes;Substance Abuse and Rehabilitation;2024-09

2. High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants;Substance Use & Addiction Journal;2023-12-29

3. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature;Addiction Science & Clinical Practice;2023-06-10

4. Commentary on Adams et al .: using administrative big data for the public good;Addiction;2022-07-11